Christina L Kong1, Nicole K Kelly1, Miel Sundararajan2, S R Rathinam3, John A Gonzales1,2, Radhika Thundikandy3, Rajesh Vedhanayaki3, Anuradha Kanakath4, Bala Murugan5, Thuy Doan1,2, Debra Goldstein6, Hassan A Al-Dhibi7, Nisha R Acharya1,2,8. 1. F.I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA. 2. Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA. 3. Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India. 4. Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India. 5. Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India. 6. Department of Ophthalmology, Northwestern University, Chicago, IL, USA. 7. Division of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia. 8. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Abstract
PURPOSE: Sub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX). METHODS: Patients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression. RESULTS: There was no significant difference in ∆CD4 between MMF and MTX at 6 months (-31.7 cells/μL for MMF compared to MTX; 95% CI: -358.2 to 294.8, P = .85) and 12 months (-78.3 cells/μL for MMF compared to MTX; 95% CI: -468.0 to 311.3; P = .69). CONCLUSION: There was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients.ClinicalTrials.gov Identifier: NCT01829295.
PURPOSE: Sub-analysis of the FAST Trial comparing change in CD4 (∆CD4) from baseline through 12 months in uveitis patients treated with mycophenolate mofetil (MMF) and methotrexate (MTX). METHODS: Patients were randomly allocated to 1.5 g twice daily MMF or 25 mg weekly MTX. Individuals with CD4 counts at baseline, 6 months (or treatment failure prior), and 12 months (or treatment failure between 6 and 12 months) were included. The association between treatment and ∆CD4 (cells/μL) was analyzed using multivariable linear regression. RESULTS: There was no significant difference in ∆CD4 between MMF and MTX at 6 months (-31.7 cells/μL for MMF compared to MTX; 95% CI: -358.2 to 294.8, P = .85) and 12 months (-78.3 cells/μL for MMF compared to MTX; 95% CI: -468.0 to 311.3; P = .69). CONCLUSION: There was no significant difference in ∆CD4 between MMF and MTX from baseline to 12 months, suggesting that MMF does not confer additional risk of CD4 lymphopenia in uveitic patients.ClinicalTrials.gov Identifier: NCT01829295.
Authors: Pamala A Jacobson; David Schladt; William S Oetting; Robert Leduc; Weihau Guan; Arthur J Matas; Vishal Lamba; Roslyn B Mannon; Bruce A Julian; Ajay Israni Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Amit C Achhra; Jialun Zhou; Francois Dabis; Sanjay Pujari; Rodolphe Thiebaut; Matthew G Law; Fabrice Bonnet Journal: J AIDS Clin Res Date: 2010-10-08
Authors: S R Rathinam; John A Gonzales; Radhika Thundikandy; Anuradha Kanakath; S Bala Murugan; R Vedhanayaki; Lyndell L Lim; Eric B Suhler; Hassan A Al-Dhibi; Thuy Doan; Jeremy D Keenan; Maya M Rao; Caleb D Ebert; Hieu H Nguyen; Eric Kim; Travis C Porco; Nisha R Acharya Journal: JAMA Date: 2019-09-10 Impact factor: 56.272